Antibodies – Page 2 – Talk Bio

Actionable Insights Powered by AI

Nxera Pharma and Antiverse Collaborate to Develop Novel GPCR-Targeted Antibody Therapeutics Using Generative AI

6 months ago talkbio0Tagged Antibodies, Antiverse, Biopharma collaboration, Generative AI, GPCR-targeted antibodies, Nxera, Pharma

Nxera Pharma, Antiverse, GPCR-targeted antibodies, Generative AI, Antibody therapeutics, Biopharma collaboration

Ottimo Pharma Emerges with David Epstein at Helm, Focusing on Novel PD1/VEGFR2 Bi-Functional Antibody

6 months ago talkbio0Tagged Antibodies, bi-functional, biotech, David Epstein, Immunotherapy for cancer, Ottimo Pharma, PD1/VEGFR2, VEGF bifunctional antibody

Ottimo Pharma, David Epstein, PD1/VEGFR2 bi-functional antibody, Cancer immunotherapy, VEGF bifunctional antibody, Biotech startup

Roche Abandons Tau Antibody Project, Returns Rights to UCB After $120M Investment

6 months ago talkbio0Tagged Alzheimer 's disease, Antibodies, Bepranemab, Investments, Roche (company), UCB, uridine triacetate

Roche, UCB, tau antibody, Alzheimer’s disease, bepranemab, $120M investment

Otsuka Seeks Accelerated Approval for Sibeprenlimab in IgA Nephropathy Following Positive Phase III Interim Results

6 months ago talkbio0Tagged Accelerated, Antibodies, Approved, Autoimmune Diseases, IGA Glomerulonephritis, Kidney Diseases, Otsuka, Phase 3 Clinical Trials, Sibeprenlimab, TNFSF13 protein, human, United States Food and Drug Administration

Otsuka, sibeprenlimab, IgA nephropathy, Phase III trial, accelerated approval, FDA, kidney disease, autoimmune disease, APRIL antibody.

FDA Places Partial Clinical Hold on BioNTech’s Anti-CTLA-4 Antibody Trial

6 months ago talkbio0Tagged Antibodies, BioNTech, Clinical Trials, Partial, Study on Hold, United States Food and Drug Administration

BioNTech, FDA, partial clinical hold, anti-CTLA-4 antibody, clinical trial, OncoC4

Merck’s RSV Antibody Clesrovimab Shows Promising Efficacy in Late-Stage Trial

6 months ago talkbio0Tagged Antibodies, Clesrovimab, Co., Infant, Late-Stage Trial, Respiratory syncytial virus

Merck & Co., RSV antibody, Clesrovimab, Respiratory syncytial virus, Infant protection, Late-stage trial results

Bavarian Nordic’s Mpox Vaccine Demonstrates Equivalent Efficacy in Teens and Adults: NIH Study

6 months ago talkbio0Tagged Adolescent (age group), Adult, Antibodies, Bavarian Nordic, Effectiveness, mpox vaccine, MVA, MVA-BN vaccine, NIH, NIH Mouse, Response process, Safety

Mpox vaccine, Bavarian Nordic, MVA-BN vaccine, Teenagers, Adults, Antibody response, Safety, Efficacy, NIH study

Sanofi’s Frexalimab Shows Promise in Multiple Sclerosis with Positive Phase 2 Results

6 months ago talkbio0Tagged Antibodies, CD40 Ligand, Frexalimab, Multiple Sclerosis, Phase 2 trial, sanofi

Sanofi, Frexalimab, Multiple Sclerosis, Phase 2 Trial, CD40L Antibody

Optimizing Expression of Multi-chain and Bispecific Antibodies: Strategies and Considerations

7 months ago talkbio0Tagged Antibodies, Antibodies, Bispecific, Cells, Chinese Hamster Ovary, CHO, Cultured Cell Line, expression vector, Metabolic Engineering, Optimization, production, Recombinants, Stable status

Bispecific Antibodies (bsAbs), Recombinant Antibody Production, Chinese Hamster Ovary (CHO) Cells, Expression Vector Optimization, Metabolic Engineering, Stable Cell Line Development

Shattuck Labs Shifts Focus to IBD Drug, Discontinues CD47 Program and Reduces Workforce by 40%

7 months ago talkbio0Tagged Antibodies, CD47 Antigen, Inflammatory Bowel Diseases, Laboratory test finding, Programs - Publication Format, Shattuck, SL 325, TNFRSF25 gene

Shattuck Labs, CD47 program, workforce reduction, IBD drug, SL-325, DR3 antagonist antibody